



Decision Diagnostics Corp.

QUARTERLY REPORT FOR OTC PINK

Supplemental Disclosures

Quarterly Report for Period Ended

September 30, 2016

Trading Symbol: **DECN**

CUSIP Number: **243443 108**

Decision Diagnostics Corp.

OTC Pink Basic Disclosure Guidelines

1) Name of the issuer and its predecessors (if any)

In answering this item, please also provide any names used by predecessor entities in the past five years and the dates of the name changes.

DECISION DIAGNOSTICS CORP. (11/25/2011-present)
INSTACARE CORP. (through 11/25/2011)

2) Address of the issuer's principal executive offices

Company Headquarters

Address 1: 2660 TOWNSGATE ROAD

Address 2: SUITE 300

Address 3: WESTLAKE VILLAGE, CA 91361

Phone: 805-446-1973

Email: info@decisiondiagnostics.com

Website(s): www.decisiondiagnostics.com

IR Contact N/A

3) Security Information

Trading Symbol: DECN

Exact title and class of securities outstanding: COMMON

CUSIP: **243443 108**

Par or Stated Value: \$0.001

Total shares authorized: 494,995,000 as of: 09/30/2016

Total shares outstanding: 81,965,005 as of: 09/30/2016

Additional class of securities (if necessary):

Trading Symbol: N/A

Exact title and class of securities outstanding: PREFERRED

CUSIP: N/A

Par or Stated Value: \$0.001

Total shares authorized: 3,738,500 as of: 09/30/2016

Total shares outstanding: N/A as of: 09/30/2016

Additional class of securities (if necessary):

Trading Symbol: N/A

Exact title and class of securities outstanding: PREFERRED SERIES "B"

CUSIP: N/A

Par or Stated Value: \$0.001

Total shares authorized: 2,500 as of: 09/30/2016

Total shares outstanding: 1,000 as of: 09/30/2016

Additional class of securities (if necessary):

Trading Symbol: N/A

Exact title and class of securities outstanding: PREFERRED SERIES "C"

CUSIP: N/A

Par or Stated Value: \$0.001

Total shares authorized: 10,000 as of: 09/30/2016

Total shares outstanding: 6,235 as of: 09/30/2016

Additional class of securities (if necessary):

Trading Symbol: N/A

Exact title and class of securities outstanding: PREFERRED SERIES "D"

CUSIP: N/A

Par or Stated Value: \$0.001

Total shares authorized: 500 as of: 09/30/2016

Total shares outstanding: NONE as of: 09/30/2016

Additional class of securities (if necessary):

Trading Symbol: N/A

Exact title and class of securities outstanding: PREFERRED SERIES "E"

CUSIP: N/A

Par or Stated Value: \$0.001

Total shares authorized: 1,250,000 as of: 09/30/2016

Total shares outstanding: 843,240 as of: 09/30/2016

Transfer Agent

Name: ACTION STOCK TRANSFER CORP.

Address 1: 2469 E. FORT UNION BLVD.

Address 2: SUITE 214

Address 3: SALT LAKE CITY, UT 84121

Phone: 801-274-1088

Is the Transfer Agent registered under the Exchange Act?* Yes: No:

*To be included in the OTC Pink Current Information tier, the transfer agent must be registered under the Exchange Act.

In April 2015 the company completed voluntary disclosure, periodic financial, and management's discussion and analysis filings (postings) with OTCMarkets, for the purposes of becoming a current voluntary filer. The company's filings were reviewed and the company was granted current filer status with OTCMarkets on April 21, 2015 and again on August 22, 2016.

List any restrictions on the transfer of security:

None

Describe any trading suspension orders issued by the SEC in the past 12 months.

None

List any stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

1:14 reverse stock split of \$0.001 par value common stock effective 11/25/2011

4) Issuance History

List below any events, in chronological order, that resulted in changes in total shares outstanding by the issuer in the past two fiscal years and any interim period. The list shall include all offerings of equity securities, including debt convertible into equity securities, whether private or public, and all shares or any other securities or options to acquire such securities issued for services, describing (1) the securities, (2) the persons or entities to whom such securities were issued and (3) the services provided by such persons or entities. The list shall indicate:

| COMMON STOCK | | | |
|--------------|--|------------------|---------------|
| Date | Description | Change in Shares | Running Total |
| 12/1/2011 | 1 for 14 Reverse Split | 8,461,032 | 8,461,032 |
| 12/19/2011 | New Issuance-Kimberly Binder | 75 | 8,461,107 |
| 12/19/2011 | New Issuance-Patrick DiParini | 200 | 8,461,307 |
| 12/30/2011 | 10% Stock Dividend | 846,669 | 9,307,976 |
| 1/3/2012 | DTC Rounding shares | (42) | 9,307,934 |
| 1/4/2012 | New Issuance-Positive Revolution Inc-S-8 | 100,000 | 9,407,934 |
| 1/11/2012 | Converted to Common-Alpha Credit | 294,000 | 9,701,934 |
| 1/18/2012 | New Issuance-Debt Conv. Andrew Edenbaum | 53,354 | 9,755,288 |
| 1/23/2012 | DTC Rounding shares | 25 | 9,755,313 |
| 3/5/2012 | New Issuance-JFS Investments Inc | 60,000 | 9,815,313 |
| 3/5/2012 | New Issuance-Garden State Securities | 60,000 | 9,875,313 |
| 3/5/2012 | New Issuance-Excell Advisors | 30,000 | 9,905,313 |
| 3/5/2012 | Return to Treasury-Positive Revolution | (100,000) | 9,805,313 |
| 3/5/2012 | New Issuance-TPC Holdings Group-ESOP-06 | 300,000 | 10,105,313 |
| 3/5/2012 | New Issuance-Cadence Consulting-ESOP-06 | 50,000 | 10,155,313 |
| 3/30/2012 | New Issuance-Alpha Credit Resources | 238 | 10,155,551 |
| 6/27/2012 | New Issuance-Rocio C Carazas-ESOP-06 | 375,000 | 10,530,551 |
| 6/27/2012 | New Issuance-Marjolein Imfeld-ESOP-06 | 375,000 | 10,905,551 |
| 9/26/2012 | Converted to Common-Centurion | 172,200 | 11,077,751 |
| 10/9/2012 | New Issuance-Aubyn Inc-ESOP-06 | 400,000 | 11,477,751 |
| 11/8/2012 | Return to Treasury-Aubyn Inc-ESOP-06 | (200,000) | 11,277,751 |
| 11/8/2012 | New Issuance-Mayer & Assoc. Esop-04 | 650,000 | 11,927,751 |
| 11/8/2012 | New Issuance-Mayer & Associates | 200,000 | 12,127,751 |
| 11/8/2012 | New Issuance-Curing Capital Inc | 400,000 | 12,527,751 |
| 11/13/2012 | Converted to Common-Centurion | 182,000 | 12,709,751 |
| 11/13/2012 | New Issuance-Econ Corporate Services | 50,000 | 12,759,751 |
| 11/13/2012 | New Issuance-Call Van Zant-ESOP-06 | 100,000 | 12,859,751 |
| 11/13/2012 | New Issuance-Darren Bankstead-ESOP-06 | 50,000 | 12,909,751 |
| 11/13/2012 | New Issuance-Axiom Financial Inc | 200,000 | 13,109,751 |
| 12/21/2012 | Cancellation-Mayer & Associates LLC | (200,000) | 12,909,751 |
| 12/21/2012 | New Issuance-Mayer & Associates LLC | 1,000,000 | 13,909,751 |
| 1/7/2013 | New Issuance-Mayer & Associates LLC | 50,000 | 13,959,751 |
| 1/7/2013 | Converted to Common-Apex Clearing | 210,000 | 14,169,751 |
| 1/7/2013 | Converted to Common-Apex Clearing | 236,600 | 14,406,351 |
| 2/15/2013 | New Issuance-TPC Holdings Group-ESOP | 1,325,000 | 15,731,351 |
| 2/15/2013 | New Issuance-Envisionte LLC-ESOP | 700,000 | 16,431,351 |

| | | | |
|------------|--|-------------|------------|
| 2/15/2013 | New Issuance-Bridgeview Capital ESOP | 700,000 | 17,131,351 |
| 2/15/2013 | New Issuance-Cadence Holdings LLC ESOP | 275,000 | 17,406,351 |
| 2/15/2013 | New Issuance-AAC Group LLC ESOP | 600,000 | 18,006,351 |
| 2/15/2013 | New Issuance-Cadence Holdings LLC ESOP | 150,000 | 18,156,351 |
| 2/15/2013 | New Issuance-St Andrews Inc | 1,000,000 | 19,156,351 |
| 2/15/2013 | New Issuance-Alan Binder ESOP | 100,000 | 19,256,351 |
| 2/15/2013 | New Issuance-Dale Richter ESOP | 100,000 | 19,356,351 |
| 2/15/2013 | New Issuance-Kimberly Binder ESOP | 50,000 | 19,406,351 |
| 2/15/2013 | New Issuance-Maria Luz Johnson-ESOP | 25,000 | 19,431,351 |
| 2/18/2013 | Converted to Common-Apex Clearing | 324,800 | 19,756,151 |
| 2/22/2013 | New Issuance-Robert Herskowitz ESOP | 500,000 | 20,256,151 |
| 2/22/2013 | New Issuance-Jeff Whitelaw | 125,000 | 20,381,151 |
| 2/22/2013 | New Issuance-Brent England | 75,000 | 20,456,151 |
| 5/9/2013 | Converted to Common-Apex Clearing | 868,000 | 21,324,151 |
| 5/10/2013 | Cancellation-Robert Herskowitz ESOP | (500,000) | 20,824,151 |
| 5/10/2013 | Cancellation-St. Andrews | (1,000,000) | 19,824,151 |
| 5/10/2013 | New Issuance-Chase Financing Inc ESOP | 350,000 | 20,174,151 |
| 5/10/2013 | New Issuance-Mayer & Associates LLC ESOP | 1,000,000 | 21,174,151 |
| 8/7/2013 | New Issuance-St Andrews Inc ESOP | 500,000 | 21,674,151 |
| 8/15/2013 | New Issuance-Robert Herskowitz ESOP | 25,000 | 21,699,151 |
| 8/27/2013 | Cancellation-Curring Capital | (200,000) | 21,499,151 |
| 8/27/2013 | Cancellation-ACC Group ESOP | (600,000) | 20,899,151 |
| 8/27/2013 | New Issuance-Benjamin Mayer ESOP | 950,000 | 21,849,151 |
| 9/20/2013 | New Issuance-SLCC Partners LLC | 1,000,000 | 22,849,151 |
| 9/20/2013 | New Issuance-Envisionte LLC-ESOP | 500,000 | 23,349,151 |
| 9/20/2013 | New Issuance-Thomas Hanson-ESOP | 250,000 | 23,599,151 |
| 9/20/2013 | New Issuance-Envisionte LLC-ESOP | 250,000 | 23,849,151 |
| 10/2/2013 | New Issuance-Joanne Broeders-ESOP | 235,300 | 24,084,451 |
| 10/2/2013 | Cancellation-Alan Binder ESOP | (100,000) | 23,984,451 |
| 10/2/2013 | New Issuance-Kimberly Binder | 100,000 | 24,084,451 |
| 10/2/2013 | Converted to Common-COR Clearing | 1,078,000 | 25,162,451 |
| 10/28/2013 | Converted to Common-Michael Belcher | 350,000 | 25,512,451 |
| 10/28/2013 | New Issuance | 2,798,728 | 28,311,179 |
| 10/30/2013 | New Issuance-Benjamin Mayer ESOP | 100,000 | 28,411,179 |
| 10/30/2013 | New Issuance-Benjamin Mayer | 300,000 | 28,711,179 |
| 10/30/2013 | New Issuance | 166,365 | 28,877,544 |
| 11/11/2013 | Conversion-Centurion Credit | 980,000 | 29,857,544 |
| 11/11/2013 | New Issuance-Benjamin Mayer ESOP | 500,000 | 30,357,544 |
| 11/11/2013 | New Issuance | 125,000 | 30,482,544 |
| 12/4/2013 | Conversion-Centurion Credit | 1,220,800 | 31,703,344 |
| 12/23/2013 | New Issuance-Mark Herskowitz ESOP | 175,000 | 31,878,344 |
| 12/23/2013 | New Issuance-Benjamin Mayer ESOP | 600,000 | 32,478,344 |
| 12/23/2013 | New Issuance | 1,200,548 | 33,678,892 |
| 1/2/2014 | New Issuance | 2,709,678 | 36,388,570 |
| 1/15/2014 | New Issuance | 748,720 | 37,137,290 |
| 1/15/2014 | New Issuance | 267,105 | 37,404,395 |
| 2/18/2014 | Conversion-Alpha Credit | 611,940 | 38,016,335 |
| 2/18/2014 | Conversion-Michael Belcher | 350,000 | 38,366,335 |
| 2/19/2014 | Conversion-Mayer & Associates | 798,000 | 39,164,335 |
| 3/28/2014 | Conversion-Alpha Credit | 523,740 | 39,688,075 |

| | | | |
|------------|--|-----------|------------|
| 3/28/2014 | New Issuance | 400,000 | 40,088,075 |
| 6/3/2014 | Conversion-Alpha Credit | 499,996 | 40,588,071 |
| 6/4/2014 | Conversion-Mayer & Associates | 1,115,660 | 41,703,731 |
| 8/14/2014 | Conversion-Alpha Credit | 245,000 | 41,948,731 |
| 8/15/2014 | Conversion-Mayer & Associates | 550,000 | 42,498,731 |
| 9/9/2014 | Conversion-Mayer & Associates | 775,000 | 43,273,731 |
| 10/28/2014 | Conversion | 675,010 | 43,948,741 |
| 1/21/2015 | New Issuance | 1,875,000 | 45,823,741 |
| 1/28/2015 | New Issuance | 850,000 | 46,673,741 |
| 2/23/2015 | Conversion-Alpha Credit | 705,124 | 47,378,865 |
| 5/11/2015 | New Issuance-Momona Capital | 235,000 | 47,613,865 |
| 5/12/2015 | Conversion-Mayer & Associates | 950,040 | 48,563,905 |
| 5/12/2015 | New Issuance-Robert Herskowitz | 950,000 | 49,513,905 |
| 5/21/2015 | New Issuance-Momona Capital | 235,000 | 49,748,905 |
| 6/1/2015 | New Issuance-Chase Financing 401K | 533,334 | 50,282,239 |
| 6/8/2015 | New Issuance-Momona Capital | 437,250 | 50,719,489 |
| 6/8/2015 | New Issuance-St Andrews | 350,000 | 51,069,489 |
| 6/29/2015 | New Issuance-Alpha Capital Anstalt | 384,537 | 51,454,026 |
| 7/27/2015 | New Issuance-Alpha Capital Anstalt | 387,907 | 51,841,933 |
| 8/24/2015 | New Issuance-Alpha Capital Anstalt | 313,022 | 52,154,955 |
| 9/16/2015 | Conversion-Mayer & Associates | 1,890,000 | 54,044,955 |
| 9/16/2015 | Conversion-Robert Herskowitz | 1,400,000 | 55,444,955 |
| 10/27/2015 | New Issuance-Alpha Capital Anstalt | 479,489 | 55,924,444 |
| 12/2/2015 | New Issuance-Alpha Capital Anstalt | 950,545 | 56,874,989 |
| 12/15/2015 | New Issuance-Alpha Capital Anstalt | 950,545 | 57,825,534 |
| 12/21/2015 | New Issuance-Alpha Capital Anstalt | 956,950 | 58,782,484 |
| 2/2/2016 | New Issuance-Alpha Capital Anstalt | 970,980 | 59,753,464 |
| 2/17/2016 | New Issuance-Alpha Capital Anstalt | 1,614,248 | 61,367,712 |
| 2/25/2016 | New Issuance-Robert Herskowitz | 750,000 | 62,117,712 |
| 3/21/2016 | New Issuance-Paradigm Capital Holdings | 1,400,000 | 63,517,712 |
| 3/21/2016 | New Issuance-Robert Herskowitz | 200,000 | 63,717,712 |
| 3/29/2016 | New Issuance-Alpha Capital Anstalt | 404,630 | 64,122,342 |
| 3/29/2016 | New Issuance-James J Loures | 500,000 | 64,622,342 |
| 4/13/2016 | New Issuance-Robert Herskowitz | 280,000 | 64,902,342 |
| 4/13/2016 | New Issuance-Robert Herskowitz | 280,000 | 65,182,342 |
| 4/13/2016 | New Issuance-Robert Herskowitz 2011 Irv TR | 140,000 | 65,322,342 |
| 4/13/2016 | New Issuance-Chase Financial | 148,160 | 65,470,502 |
| 4/13/2016 | New Issuance-Mark Herskowitz | 185,195 | 65,655,697 |
| 4/13/2016 | New Issuance-Andrew Schoenzeit | 37,040 | 65,692,737 |
| 4/13/2016 | New Issuance-Robert Herskowitz 2011 Irv TR | 431,376 | 66,124,113 |
| 4/26/2016 | New Issuance-LICGO Partners | 1,837,500 | 67,961,613 |
| 4/26/2016 | Conversion-Mayer & Associates | 200,200 | 68,161,813 |
| 5/2/2016 | New Issuance-Robert Herskowitz | 472,106 | 68,633,919 |
| 5/5/2016 | New Issuance-Alpha Capital Anstalt | 998,099 | 69,632,018 |
| 5/17/2016 | New Issuance-Alpha Capital Anstalt | 422,669 | 70,054,687 |
| 5/17/2016 | New Issuance-Navesink | 625,000 | 70,679,687 |
| 5/18/2016 | New Issuance-LICGO Partners | 525,000 | 71,204,687 |
| 5/18/2016 | Conversion-Mayer & Associates | 220,000 | 71,424,687 |
| 6/1/2016 | New Issuance-Alpha Capital Anstalt | 814,314 | 72,239,001 |

| | | | |
|-----------|---|-----------|------------|
| 6/6/2016 | New Issuance-Mark Herskowitz | 1,000,000 | 73,239,001 |
| 6/6/2016 | New Issuance-Chase Financing Inc Profit Sh. | 1,050,000 | 74,289,001 |
| 6/6/2016 | New Issuance-Robert Herskowitz | 280,000 | 74,569,001 |
| 6/6/2016 | New Issuance-Robert Herskowitz 2011 Irv TR | 70,000 | 74,639,001 |
| 6/8/2016 | New Issuance-Alpha Capital Anstalt | 484,148 | 75,123,149 |
| 6/27/2016 | New Issuance-Navesink | 625,000 | 75,748,149 |
| 7/18/2016 | New Issuance-TPC Holdings Group | 150,000 | 75,998,149 |
| 7/21/2016 | New Issuance-Robert Herskowitz | 690,000 | 76,688,149 |
| 7/21/2016 | New Issuance-Robert Herskowitz 2011 Irv TR | 70,000 | 76,758,149 |
| 7/21/2016 | New Issuance-Chase Financial | 945,000 | 77,703,149 |
| 8/2/2016 | New Issuance-Navesink | 625,000 | 78,328,149 |
| 8/29/2016 | New Issuance-Alpha Capital Anstalt | 954,925 | 79,283,074 |
| 9/7/2016 | New Issuance-Chase Financial | 945,000 | 80,228,074 |
| 9/19/2016 | New Issuance-Alpha Capital Anstalt | 521,784 | 80,749,858 |
| 9/19/2016 | New Issuance-Mark Herskowitz | 805,147 | 81,555,005 |
| 9/19/2016 | New Issuance-Marc Berger | 400,000 | 81,955,005 |

PREFERRED B STOCK

| Date | Description | Change in Shares | Running Total |
|-----------|---|------------------|---------------|
| 3/23/2011 | New Issuance-Centurion Credit Resources | 1,000 | 1,000 |

PREFERRED C STOCK

| Date | Description | Change in Shares | Running Total |
|------------|--|------------------|---------------|
| 1/4/2012 | New Issuance-Michael Belcher | 1,250 | 1,250 |
| 8/27/2013 | New Issuance-Lathrop Gage LLC | 1,500 | 2,750 |
| 10/28/2013 | Conversion-Michael Belcher | (70) | 2,680 |
| 2/18/2014 | Conversion-Michael Belcher | (70) | 2,610 |
| 12/30/2015 | New Issuance-Navesink Device Initiatives | 1,475 | 4,085 |
| 3/21/2016 | New Issuance-Paradigm Capital | 800 | 4,885 |
| 4/26/2016 | New Issuance-LICGO Partners | 1,050 | 5,935 |
| 4/26/2016 | New Issuance-Paradigm Capital | 325 | 6,260 |
| 5/17/2016 | Conversion-Navesink Device | (125) | 6,135 |
| 5/18/2016 | New Issuance-LICGO Partners | 300 | 6,435 |
| 5/18/2016 | New Issuance-Paradigm Capital | 50 | 6,485 |
| 6/27/2016 | Conversion-Navesink Device | (125) | 6,360 |
| 8/2/2016 | Conversion-Navesink Device | (125) | 6,235 |

PREFERRED E STOCK

| Date | Description | Change in Shares | Running Total |
|------------|-------------------------------------|------------------|---------------|
| 5/17/2011 | New Issuance-Centurion Credit | 135,000 | 1,095,300 |
| 1/11/2012 | Converted to Common | (21,000) | 1,074,300 |
| 3/30/2012 | New Issuance-Alpha Credit Resources | 124,700 | 1,199,000 |
| 9/26/2012 | Converted to Common | (12,300) | 1,186,700 |
| 11/13/2012 | Converted to Common | (13,000) | 1,173,700 |
| 1/7/2013 | Converted to Common | (15,000) | 1,158,700 |

| | | | |
|------------|---|-----------|-----------|
| 1/7/2013 | Converted to Common | (16,900) | 1,141,800 |
| 2/18/2013 | Converted to Common | (23,200) | 1,118,600 |
| 5/9/2013 | Converted to Common | (62,000) | 1,056,600 |
| 10/2/2013 | Converted to Common | (77,000) | 979,600 |
| 11/11/2013 | Conversion-Centurion Credit | (70,000) | 909,600 |
| 12/4/2013 | Conversion-Centurion Credit | (87,200) | 822,400 |
| 1/15/2014 | Conversion-Alpha Credit | (53,480) | 768,920 |
| 2/18/2014 | New Issuance-Mayer & Associates | 125,000 | 893,920 |
| 2/18/2014 | Conversion-Alpha Credit | (43,710) | 850,210 |
| 2/19/2014 | Conversion-Mayer & Associates | (57,000) | 793,210 |
| 3/28/2014 | Conversion-Alpha Credit | (37,400) | 755,810 |
| 6/3/2014 | Conversion-Alpha Credit | (35,714) | 720,096 |
| 6/4/2014 | Conversion-Mayer & Associates | (79,690) | 640,406 |
| 8/14/2014 | Conversion-Alpha Credit | (17,500) | 622,906 |
| 8/15/2014 | Conversion-Mayer & Associates | (39,285) | 583,621 |
| 9/9/2014 | Conversion-Mayer & Associates | (55,357) | 528,264 |
| 10/28/2014 | Conversion-Mayer & Associates | (30,358) | 497,906 |
| 1/21/2015 | New Issuance-Robert Herskowitz | 100,000 | 597,906 |
| 1/21/2015 | New Issuance-Mayer & Associates | 135,000 | 732,906 |
| 1/21/2015 | New Issuance-Alpha Credit Resources | 67,860 | 800,766 |
| 2/23/2015 | New Issuance-Alpha Credit Resources | (50,366) | 750,400 |
| 5/12/2015 | Conversion-Mayer & Associates | (67,860) | 682,540 |
| 5/12/2015 | New Issuance-Robert Herskowitz | 30,000 | 712,540 |
| 7/27/2015 | New Issuance-Chase Financing | 75,000 | 787,540 |
| 9/16/2015 | Conversion-Mayer & Associates | (135,000) | 652,540 |
| 9/16/2015 | Conversion-Robert Herskowitz | (100,000) | 552,540 |
| 9/16/2015 | New Issuance-Chase Financing | 135,000 | 687,540 |
| 2/25/2016 | New Issuance-Robert Herskowitz | 100,000 | 787,540 |
| 3/21/2016 | New Issuance-Mayer & Associates | 14,300 | 801,840 |
| 4/26/2016 | Conversion-Mayer & Associates | (14,300) | 787,540 |
| 4/26/2016 | New Issuance-Mayer & Associates | - | 787,540 |
| 5/18/2016 | Conversion-Mayer & Associates | (14,300) | 773,240 |
| 6/6/2016 | New Issuance-Mark Herskowitz 401K Trust | 100,000 | 873,240 |
| 6/6/2016 | New Issuance-Chase Financing Inc Profit Sh. | 35,000 | 908,240 |
| 6/6/2016 | New Issuance-Chase Financing | 100,000 | 1,008,240 |
| 6/6/2016 | Conversion-Chase Financing Inc Profit Sh. | (75,000) | 933,240 |
| 7/21/2016 | Conversion-Chase Financing Inc | (67,500) | 865,740 |
| 7/21/2016 | Conversion-Robert Herskowitz | (30,000) | 835,740 |
| 9/7/2016 | Conversion-Chase Financing Inc | (67,500) | 768,240 |
| 9/19/2016 | New Issuance-Chase Financing Inc Profit Sh. | 75,000 | 843,240 |

- A. Whether the certificates or other documents that evidence the shares contain a legend (1) stating that the shares have not been registered under the Securities Act and (2) setting forth or referring to the restrictions on transferability and sale of the shares under the Securities Act.

See above

5) Financial Statements

SEE FINANCIAL STATEMENTS ATTACHED TO THIS DISCLOSURE STATEMENT

6) Describe the Issuer's Business, Products and Services

Overview

Decision Diagnostics Corp. is a worldwide prescription and non-prescription diagnostics and home testing products distributor and the manufacturer of the Genstrip 50 and GenUltimate! glucose test strips, both Class II medical devices for at-home use for the measurement of glucose. The company also has its GenSure! glucose test strip, a product for off-shore sales, and GenChoice! glucose test strip, both alternative test strips now in advanced development. The U.S. FDA, in a manner similar to prescription drugs, regulates diagnostic test kits and at-home patient testing products a similar but streamlined process, to the regulation of prescription medicine. The regulatory standard used for the Genstrip 50 was the 510k pre-market and post-market processes. The company from 2005 and until 2013, contracted with independent pharmacies for use of their prescription drug distribution licenses. However, the brand name products we have distributed, for the most part, do not require a doctor's prescription for anything other than insurance benefit compliance. Our business model works well in this regulated environment, although the financial benefits have been stressed by major changes made to the Medicare plan that have led to substantially lower rates of reimbursement.

Our subsidiaries, Pharma Tech Solutions, Inc. and PDA Services, Inc. operate in several healthcare products channels. In addition our subsidiary Decision IT Corp. engages in the acquisition and holding of Intellectual Property including Patents and Trademarks and specialty manufacturing equipment acquired for our Korean contract manufacturer of our GenUltimate! and our in development GenSure! and GenChoice! products. Our new subsidiary Pharmatech Sensor Development Corp. manages an inventory credit line to finance inventory purchases of our Genstrip 50 and GenUltimate! products. The company has discontinued its GenStrip 50 product and is currently selling the last of its inventory.

From time to time, when economic conditions warrant and given market conditions, we distribute brand name prescription and non-prescription diagnostics products, as well as several lines of ostomy, wound care and post-surgery medical products, although these healthcare channels have also undergone two major market changes and disruptions since July 2013 and we have determined that we will maintain our contacts but will refrain from competing. Our main product is the Genstrip 50, a rebranding and redevelopment of the original Shasta Technologies Genstrip, and our new GenUltimate! Both glucose test strips are of our manufacture. The original GenStrip was cleared for market by the FDA on November 30, 2012. By virtue of our written agreements with Shasta in 2011, we were granted an irrevocable license to prosecute their 510k application with the U.S. FDA, and we succeeded. We introduced the original Genstrip in March 2013. We then acquired Genstrip from Shasta Technologies LLC on March 20, 2014 and in late June 2014 we made the branding changes. We began work on the GenUltimate! product in July 2015 and introduced this improved test strip (vs. our GenStrip) in April 2016.

Shasta Technologies LLC, the original specifications provider of GenStrip, had an extremely difficult relationship with the US FDA and was the subject of a detailed and damning FDA Warning Letter on April 8, 2014, and when they refused to respond to this Warning Letter, the FDA then broadcast a worldwide Safety Notice on April 29, 2014, effectively ending Shasta's ability to be a product design specifier and manufacturer, due to a total lack of regulatory adherence in the highly regulated medical device industry.

The company's acquisition of Genstrip (now Genstrip 50) was fortuitous in its timing given the finality and outcome of Shasta Technologies' troubles with the FDA.

The worldwide market for at-home blood glucose testing is an estimated \$12.5 billion. Genstrip50 competes directly with one of the largest worldwide platform manufacturers the venerable Johnson & Johnson (Lifescan Inc.). GenStrip 50 and GenUltimate! were developed for use on their OneTouch Ultra legacy system for at-home blood glucose testing, a system currently used daily by over 3 million diabetes afflicted Americans. Genstrip 50 competes in the overall at-home testing market by offering an economical solution to former users of the legacy platform provider's product. The company's GenUltimate! product, designed to meet new European Union standards is a much improved version. Our business model is unique to this market channel as our major business focus is directed toward diabetics who have attempted a change of their glucose monitoring platforms (systems) or those currently using the J&J legacy products but are dealing with escalating prices and lower insurance reimbursements. At the time of the introduction of GenStrip in March 2013, J&J controlled just under 30% of this market and 100% of its own Lifescan, Inc. OneTouch Ultra market.

Throughout 2012 in anticipation of the introduction of Genstrip, we evaluated our brand-name distribution model, a model that provided streams of revenue but extremely low profit margins, and over the course of the last 30 months we have phased out sales of those brand name products that had been a backbone of our distribution business. In addition the brand name products distribution business created a situation where we were selling products that competed directly with our Genstrip 50. Phasing out these brand name products lowered our order intake but allowed us to become a manufacturer, at a higher level in the greater market channel.

The company will continue to direct its marketing efforts to ambulatory and semi-ambulatory older Americans afflicted with diabetes and complications caused by diabetes and old age. The company, originally a medical IT company with proprietary IT product lines, acquired its medical products distribution business in late 2004 through a merger with Phoenix, Arizona based CareGeneration, Inc. We have grown the original CareGeneration business through subsequent acquisitions of private businesses and strategic partnerships with larger private pharmacies.

On November 1, 2011 we completed the acquisition of Diagnostic Newco LLC from its owner Kimberly Binder. Diagnostic Newco LLC was a design company that specialized in product packaging design, medical products advertising design and graphic art. Ms. Binder has joined the staff of the company's Pharma Tech Solutions, Inc. subsidiary specifically for these purposes, and has worked closely with the contract manufacturers for Genstrip 50 and GenUltimate!, making subtle changes to packaging design and more recently integrating the new FDA UDI product identification data system, among other responsibilities. She is also responsible for the package design for new diagnostic products the company is currently working on, including the upcoming GenSure! and GenChoice! products. Ms. Binder is also owner of GenstripDirect LLC and Full Circle Diabetes LLC, her own distribution companies, which she operates separately from her (Decision Diagnostics Corp. and Pharma Tech Solutions, Inc.) company related responsibilities.

We also intend to acquire additional private companies, or partner with small engineering companies that have developed technology requiring either regulatory approval, distribution expertise or both. In December 2011 we made another small acquisition, to acquire the services of Mr. Patrick DeParini. We are moving quickly to achieve our goal of becoming a vertically integrated, full service value added provider of products and services to an ever-growing market. The at-home diabetes testing market continues to grow as diabetics continue to be diagnosed and treated. The market for diabetes testing products is expected to grow from a current \$22.5+ billion worldwide base in 2016 to over \$25 billion in 2018.

The company's current proprietary product offering, cleared by the FDA for commercial distribution on November 30, 2012, are the Genstrip 50 and its newer version GenUltimate! blood glucose diagnostic test strip for at-home testing. Genstrip is a product originally conceived by Shasta Technologies LLC, who proved incapable of attaining the necessary regulatory approvals after two attempts, 2009 and 2010/2011. The original Shasta product was acquired by our Pharma Tech subsidiary on March 20, 2014, and fits into a diagnostic product niche, fitting nicely into the world-wide self-test (home test) market that has been growing at a 15% annual rate. Since Genstrip 50 and GenUltimate! are rather unique product offerings, employing a brand name razor blade only model (diagnostic test strip) into a razor (diagnostic meter)-- razor blade (diagnostic test strip) market, the Genstrip 510(k) application made for unusual challenges for the FDA and an educational challenge and opportunity for the company. In fact, the company only recently (March 15, 2016) concluded its dealings with the FDA pre and post market review staff, an on-going process that was begun on a sour note by Shasta in October 2009. The company believes that future product offerings that will be regulated by the FDA will be a much smoother process, particularly since receipt of this landmark March 15 ruling by the U.S. FDA, covering our third party developed diagnostics. Since the company plans additional similar products in the future for other diagnostic platforms, in fact a product announced still in the current reporting year, the Genstrip experience, however slow and unresponsive it was, has provided lessons and experience which is already being put to use.

Two years (and growing) is a standard development to market timeline for in-vitro diagnostic products similar to Genstrip. As a result of previous delays and failures by Shasta Technologies in completing its FDA approval application [510(k)] and then problems Shasta encountered in prosecuting its two original applications with FDA staff, the company changed its contractual responsibilities and obligations in June 2011 to include program management, regulatory process management, management of the manufacturing forecasting and distribution processes, and new products planning and development. Further (eventually fatal) on-going problems encountered by Shasta, which on their face proved irresolvable, presented the company with an opportunity. On March 20, 2014 our Pharma Tech Solutions, Inc. subsidiary acquired the intellectual property, the marks, and the GenStrip cleared 510(k). Subsequently we accomplished a rebranding of the original Genstrip product (GenStrip 50), built manufacturing protocols, implemented a robust Quality System throughout 2014 and 2015, and then developed the improved GenUltimate! product. GenUltimate! has become the only product of the original Genstrip line that will be packaged to conform with the FDA UDI standards, and was released as UDI compliant as of September 24, 2016. Manufacturing of Genstrip 50 has ended and on-going sales will continue for the remainder of 2016, but will not include the FDA UDI packaging.

In June 2010 the company was approached by the largest retailer in the world for the distribution and sale of the Genstrip product, then about to enter the 510k regulatory review process, at over 5,000 retail stores worldwide. A contract with this retailer was negotiated in September 2010 and subsequently renegotiated and renewed in April 2011, and as soon as the retail contract was agreed to and as a means to conduct market research, the company began seeking pre-conditioned letters of intent (pre-orders) for Genstrip, while continuing the prosecution of the 510(k) application on behalf of Shasta Technologies before the FDA. Discussions with this retailer and other similarly situated retailers had been on a litigation induced hiatus since our litigation with Lifescan, Inc. began in earnest in late March 2013. Lifescan Inc., the diabetes testing division of Johnson & Johnson sued the company in three separate suits, all in Federal court, beginning in September 2011. These suits proved costly in that their intended purpose was to keep the Genstrip product off of retail market shelves. Until these suits were settled in May 2016, the company's marketing abilities were severely limited. The settlements provided a hard-fought victory for the company. During the just ended 3Q 2016, we settled these lawsuits in a novel manner, where Johnson & Johnson paid the company a settlement amount and also granted the company licenses to J&J patents -- the larger value gained from this 5-year legal battle. In March 2016, prior to its settlement, the company's Pharma Tech Solutions, Inc. and Decision IT Corp. subsidiaries brought suit against Lifescan, Inc. in Nevada Federal court for patent infringement, the company alleging that Lifescan, Inc.'s OneTouch Ultra product was and had been infringing both of the company's patents.

Currently the diabetes testing market is dominated by four large pharmaceutical manufacturers who provide very similar and equally focused products, selling at essentially equal prices. Genstrip's introduction, even with the fits and starts, will not only allow the company to achieve market share but because of the business model currently employed by Genstrip 50 (and now GenUltimate!) is different than those models employed by the major market players, the company may be able to alter the market dynamics, lowering average price (which has occurred) or allowing for increased testing by diabetics for a lesser price, thereby affecting all market segments. The company's major market focus is to pharmacy chains, grocery chains with in-store pharmacies, large all purpose retailers with in-store pharmacies, and group buying and chain pharmacy organizations. In the recent past our model might have been called a private label model or a value added model, but with the advent of the July 2013 changes to Medicare (and followed by private insurers) and the October 2016 reimbursement engineering, pharmacy business models are now blurred.

The company has also implemented a very successful "direct to diabetic" business model and has (independently or along with our distributors) executed on-line agreements with several (as of August 10) of the largest retail chains, diabetic supply co-operatives, group purchasing organizations, as well as on-line mass merchandisers such as Amazon.com, Ebay, Walmart, Jet.com and approximately 500 other on-line cooperatives.

The company has also offered information technology solutions in several medical care market channels by providing physicians with information at the point of care. Our products, unlike those from many other medical information companies, make use of smart cell phones such as the Apple iPhone, the Palm Pre, the Google Droid and a wide selection of Microsoft Windows based smart phones and operate in either in a wireless or "wired" mode, which allow physicians to carry, access and update their patients' histories, also known as electronic medical records or EMR, medication data, and best care guidelines - *all at the point of care*, or from any other location the physician may be located. In addition, the company's products employ proprietary mathematical game theory features adapted by the company for medical use that allow acceptance of diagnoses and treatment protocols where the medical information may have originated from one or several locations and one time or several times. Since the advent of "Obamacare," promising products like our own struggled to gain market acceptance in a reimbursement challenged market. The company cannot yet venture opinions or forecasts for its IT products now that the new administration While we have kept up with the evolving regulatory changes, we do not foresee implementation of our products and networks in the near future.

In October 2014 we adopted a value added/private label business model to address the issues brought to our market by the radical reimbursement changes by the federal Medicare program. We also hired a market executive with over 40 years of experience

to implement our new strategy. We have since first supplemented and then upon his retirement, replaced this expert with a large retail product sourcing organization, Retail Monster, who represent our products to large drug chains (“big box pharmacy”), large retailers, chain grocers and the like. The efforts of Retail Monster, hired at the end of 1Q 2016, will be aided greatly by the company’s recent success with the explosively growing on-line Marketplaces, many sponsored by the large retail pharmacies, retail stores. These Marketplaces are fast growing sister organizations to these retailers. The company’s recent successes in the on-line marketplaces has given the company a beachhead in this market as the uncertainty brought on by the J&J lawsuits has (finally) waned.

Since March 2015 when we first we acquired special intellectual property and specialty manufacturing equipment which will shall serve our business interests now and into the future. We have increasingly turned to Alpha Capital Anstalt (“Alpha”) and Licgo Partners and their sister fund Navesink Device Initiatives, whereby these organizations either purchased an 18-month 15% OID derivative instruments or Preferred C stock units, to facilitate the acquisition of intellectual property or manufacturing equipment, or to finance our growth. In 1Q and 2Q 2016 we completed additional financing transactions with both Alpha and Licgo. Our most recent transactions with Alpha also financed an inventory credit line for the company so that we can meet the requirements of the largest retailers and maintain at least \$350,000 in stock on hand at any time. Alpha also financed our acquisition of new specialty manufacturing equipment to facilitate our contract manufacturer in Korea as they develop our new GenChoice! product.

In the Fall of 2014 the company announced its Discretion cloud wireless glucose monitoring product concepts, which will be manufactured for the company according to spec by its Korean contract manufacturer. In April 2015 the company entered into discussions with [HMD Biomedical, Inc.](#) in Taiwan for the importing of HMD’s FDA cleared “Cloudia,” product as a placeholder until the company’s Discretion Messenger product for children will be ready. We ended our discussions with HMD Biomedical in October 2016, after determining that the “Cloudia” product was not robustly developed enough for North American markets and to further develop this product would require another 510(k) approval from the U.S. FDA. The company was concerned that a revised “Cloudia” would be able to meet the more stringent ISO 15197:2013 and FDA Guidance 2014 requirements. To that end, the company’s exclusive agent in Korea was contacted by the Korean government, who apparently are willing to finance the Discretion Messenger initiative through its advanced development, clinical trials and FDA prosecution. Further, the company has locked down a distribution partner in Korea who has placed a substantial order for GenUltimate! for delivery during 4Q 2016 and again in 1Q 2017. Different than, for example, an NIH grant, this grant from the Korean government, if accepted by the company, would include investment in the company’s contract manufacturer as well. The company has recently completed a further development of its MD@Hand product, allowing diabetic users of the company’s Discretion products to monitor and track their diabetes treatment and testing on their smart cell phones. The company plans to spin-off its other MD@Hand and Residenceware technologies in a larger M&A transaction now in process.

We have received multiple inquiries from companies interested in perhaps collaborating with the company for the implementation of its cell phone centric technologies MD@Hand and MD@Work. However, the market available for products similar to MD@Hand and MD@Work has changed since its introduction in 2009. The legal challenges to the new health care law and the federal government’s inability to enact regulations have altered the landscape, again. We remain in discussions with multiple concerns for the marketing of our MD@ products, and any agreement we may enter will require us to provide contract software programming, providing a new source of revenue for the company. In addition to any proposed partnerships, we continue to discuss alternative propositions with other interested companies ranging from clinical laboratories, service organizations owned or aligned with medical health insurers, a medical content provider and legacy healthcare systems companies. There remains sustained interest in our MD@ technology. We may or may not entertain additional proposed partnerships for our implementation of the cell phone centric technologies, which has been hindered, as has the overall market, by the slow implementation of regulations, protocols and data formats by the Federal government, as well as a change in previously announced Federal government monetary incentives.

In May 2010, we entered into agreement with Shasta Technologies, Inc. and Broadtree, Inc. This agreement granted our Pharma Tech Solutions, Inc. subsidiary the exclusive marketing rights to a new diagnostic product not yet on the market named Shasta Genstrip (“Genstrip”). The Genstrip product was developed to compete against the market leader in the then \$6.5 billion at home testing market. Shasta was in default of this 2010 Agreement. Penalties under that agreement and monies owed totaled in excess of \$2 million in “delay” penalties, which they were unable to pay. In April 2011, the company renegotiated its agreement changing its many roles and adding responsibility for regulatory approval, manufacturing and forecasting, international sales and additional sales markets in the U.S. Shasta defaulted under this agreement as well. On March 20, 2014 we acquired the GenStrip intellectual property, its marks and the cleared 510(k). On April 30, 2014 we first implemented our FDA mandated Quality Plan and are now operating as the manufacturer (operator) of the GenStrip 50. We have implemented subsequent Quality Plans with our Korean contract manufacturer for our GenUltimate! product.

In August 2016 the company settled an insurance matter with Shasta covering legal fees associated with the 2011 and 2012 lawsuits brought by Lifescan, Inc. This settlement included a stipulation by Shasta to cease contacting and sharing confidential documents with persons who identified themselves as DECN shareholders. The stipulation does not preclude the company from

pursuing Shasta, its principals and these “shareholders” in its omnibus lawsuit brought against Shasta et al. in 2014. The company plans to amend its 2014 complaint to name additional Defendants including those persons who owned stock in the company who may have traded stock in the market based on information provided by Shasta.

We currently employ five professionals at our executive business office located at 2660 Townsgate Road, Suite 300, Westlake Village, California 91361. In addition, we maintain two full-time and seven part-time positions located throughout the United States. We also maintain a Quality Assurance office in York, PA and our exclusive agent in Seoul, Korea maintains another office as a means to fulfill our quality commitments to the FDA. Our telephone number is (805) 446-1973 and our website addresses are www.decisiondiagnostics.com and www.pharmatechdirect.com and www.genultimate.com.

As a part of the company’s strategic plans, we have applied (to register) for seven Trademarks with the USPTO. The company’s Genstrip product is a registered Trademark of Shasta Technologies LLC. Our applications were filed with the USPTO in 1Q and 2Q 2015. The company intends to use these Marks, as granted, to brand new products, rebranding of existing products, and the establishment of a family of Marks associated with our company and its place in our industry. As of August 10, 2016 the company has received registration confirmation from the USPTO for the following Marks:

“Alltara!”
“GenUltimate!”
“Discretion Messenger”
“GenSure”
“GenChoice!”

Beginning in the 4th Quarter 2015 and through first Quarter 2016 the company suffered severe inventory shortage of the Genstrip 50 product at various times, owing to the timing of the various settlements with Johnson & Johnson. For some period of time the company’s contract manufacturer was unable, due to their settlement with Johnson & Johnson, to ship to the company certain quantities of the Genstrip product. This problem began to clear up in late March 2016, and with the advent of adding the GenUltimate! product from Korea, shortages have been alleviated. The company’s capacity for Genstrip 50 and GenUltimate! production is now 500,000 packages per month (50 strips per package). Recently, a mega- retailer that we have contracted with has requested minimum inventories of finished product of 350,000. We expect other retailers to make similar requests.

Contingencies and Litigation

We transact commerce in several medical products market channels. We also transact commerce by licensing our proprietary medical software that functions by moving confidential medical data through our proprietary medical information technology devices and networks. Our original Genstrip product required initial regulatory approval by the USFDA as well as on-going USFDA approvals during the product life cycle. Further, Genstrip required medical patient trials and competes directly with a major platform manufacturer. We insure against any claims made against the company for our Genstrip product.

Healthcare, especially those segments where the company competes, is a very litigious. Competing companies often use litigation as a marketing tool, bringing litigation as a means to protect market share and limit market exposure. The medical industry is also intertwined. From time to time, we may become involved in claims and litigation that arise out of the normal course of business, such as litigation that emerges from disputes over damaged, missing or contaminated product, litigation that arises over payment disputes or claims of fair value. We may also become involved in disputes that arise over the business or business practices of our suppliers, payers and customers. It is not uncommon in our industry to find that a litigant has filed claims in multiple jurisdictions involving the same transaction or a single transaction. The company maintains substantial insurance coverage against suits that may arise over issues of damaged, recalled or counterfeit product and other product liability issues. The company has also been a victim of the unapproved acts of prior management. These acts have resulted in claims from individuals and entities since the Board relieved former management of duty in 2006. Nonetheless, these claims have resulted in the use of management time and company resources to investigate, litigate, or settle. In addition, the company accrues contingent legal fees and product liability fees. As of September 30, 2016, our accrual was \$245,069.

From time to time, the company may also be subject to demands from individuals or entities. These demands and disputes may consume management time and company resources. Other than as noted below, if there is such a disclosure, there are no pending matters at the current time that in management’s judgment may be considered potentially material to us.

We were in litigation with Lifescan Inc. a subsidiary of Johnson & Johnson beginning in September 2011. Lifescan had maintained throughout that our Genstrip product infringed on three of their patents. One of these patents has become the subject of peripheral

litigation activities, and two Appeals (one for each side) to the U.S. Appeals Court for the Federal Circuit (the patents appeals court). In January 2016 the Court of Appeals for the Federal Circuit ruled in its Mandate that this one foundational patent and the claims made by the assignee Lifescan, Inc. was struck (killed) due to obviousness (a clever wording meant to obscure a connection between the Lifescan, Inc. invention and earlier generation technologies dating back to the late 1970s). Throughout this Appeal process, and a litigation process waged through the USPTO, the company prevailed. Recently, as a result of certain claims and allegations made by Lifescan after the close of the USPTO final determination (in favor of the company), the office of the Solicitor General has intervened against Lifescan Inc. in the Federal Circuit court and was of great assistance in getting the Lifescan, Inc. patent revoked. Nonetheless the seeming baseless allegations and claims made by Lifescan against the company have taken their toll, limited our ability to sell Genstrip 50 to large entities (“big box stores”) and greatly extended the court processes.

In the Spring of 2013, fearing the impact of the Genstrip product in an open market, Lifescan took it upon themselves to violate a court protective order and prepared and sent out thirty page certified (veiled threat) letters to customers of the company and the customers of the company’s customers, making it clear to these entities that should they do business with the company, or buy Genstrip product from others doing business with the company, they could or would be added as defendants to the patent infringement suit. Most independent pharmacies in the U.S. sell less than a case (24 boxes) of a single brand of glucose test strips monthly. It is easy to ascertain that an independent pharmacy would choose not to “poke the bear” and risk a several hundred thousand dollar defense, rather than halting sales of Genstrip. Some large retailers were visited or called by Lifescan management and provided with face to face veiled threats. Lifescan even calculated that by breaching the protective order, the sanctions they would be assessed would amount to far less than the business loss they would otherwise suffer. Slowly however, the litigation environment enjoyed by Lifescan changed.

In December 2014 counsel for Lifescan wrote a letter to the trial judge who is hearing all three patent matters. This letter outlined a series of issues involving Lifescan’s lead damages “expert” during litigation proceedings. Lifescan’s expert claimed educational and qualification credentials that were not true at the time of the “expert” testimony, and are not true even today. This expert also assisted Lifescan’s counsel in at least one other case, and other companies’ counsels in unrelated cases. Testimony from this expert, in each instance, allowed the Plaintiffs in these cases to secure court rulings to the detriment of the Defendants. In the company’s case this expert was used twice and assisted Lifescan to receive preferential treatment from the court for setting of a litigation bond to cover potential damages, wherein the “expert” through testimony limited the scope and calculation of damages in the setting of the damages protection afforded by the litigation bond and the damages resulting from Lifescan’s violation of the court protective order. Lifescan’s letter admonition came over a year after their successful use of this “expert.”

In March 2016 the company filed suit in the Federal District Court of Nevada against Lifescan, Inc., Lifescan Scotland, Ltd. and Johnson & Johnson, citing infringement of two patents owned by the company. After an exchange of demand letters and posturing by the Defendants, including Defendant’s Motion to Dismiss, the company at that time it expects to amend its suit and name other “infringers” as well as adding additional counts to the suit. Federal rules for patent infringement suits have changed, and these suits are now adjudicated over an 18-24 month period. In addition, there are five scheduled Mediations in front of a Federal Judge Magistrate pushing the process along.

On May 20, 2016 the company settled all of Lifescan’s patent infringement claims as well as the company’s Anti-trust and false advertising counter-claims against Lifescan, Inc. and Johnson & Johnson. Neither side in these litigations was a winner, but the company did receive settlement monies and other compensation. The amount of the settlement monies received by the company was confidential, as is often the case when Plaintiffs dismiss or lose a complex case, but confidentiality aside, the entire settlement was structured as a license agreement whereby Lifescan, Inc. granted licenses to the company for its test strip patents in return for accommodations regarding the anti-trust and false advertising claims made by the company. The licenses to the Lifescan Inc. patents were of great value to the company in the overall settlement.

A. Date and State (or Jurisdiction) of Incorporation:

INCORPORATED IN THE STATE OF NEVADA ON MARCH 2, 2001 AS ATR SEARCH CORPORATION

B. the issuer’s primary and secondary SIC Codes;

5122, 7371

C. the issuer’s fiscal year end date;

DECEMBER 31

D. principal products or services, and their markets;

Genstrip 50 Glucose Test Strips and GenUltimate! Glucose Test Strips for use with Johnson & Johnson Lifescan glucometer, GenSure! and GenChoice! glucose test strips. MD@Hand medical communication and EMR software for use with smart cell phones.

7) Describe the Issuer’s Facilities

We currently maintain an executive office at 2660 Townsgate Road, Suite 300, Westlake Village, CA 91361. The space consists of approximately 2,300 square feet. The monthly rental for the space is \$2,170 per month on a month-to-month basis. Our Pharma Tech subsidiary maintains a facility for quality assurance and control of its FDA QSR at 750 Borom Road, York, PA

8) Officers, Directors, and Control Persons

The goal of this section is to provide an investor with a clear understanding of the identity of all the persons or entities that are involved in managing, controlling or advising the operations, business development and disclosure of the issuer, as well as the identity of any significant shareholders.

A. Names of Officers, Directors, and Control Persons. In responding to this item, please provide the names of each of the issuer’s executive officers, directors, general partners and control persons (control persons are beneficial owners of more than five percent (5%) of any class of the issuer’s equity securities), as of the date of this information statement.

Our executive officers, directors, and key employees are:

| <u>Name</u> | <u>Age</u> | <u>Position</u> |
|-----------------|------------|--------------------------------------|
| Keith Berman | 63 | Chief Financial Officer and Director |
| William Lyons | 63 | Director |
| Robert Jagunich | 69 | Director |

Our shareholders elect our directors and our Board of Directors appoints our officers. As of the date of this filing, we have not held an annual meeting. All current directors have been held over until such time the annual meeting is held. Vacancies in our board are filled by the board itself. Set forth below are brief descriptions of the recent employment and business experience of our executive officers and directors.

Keith Berman has served as President, Chief Financial Officer, Secretary, Treasurer and Director of the Company since January of 2003. For over the past 17 years, Mr. Berman has been involved in the development of healthcare software including Intranet and Internet systems. From July 1999 to present, Mr. Berman has held the position of President, founder and director of Caredecision.net, Inc. a private company engaged in e-health technology development. From March 2001 through June 2002 Mr. Berman also held the Position of President and Director of Medicus, Inc. From January 1996 to June 1999 Mr. Berman was the President and founder of Cymedix, the operating division of Medix Resources, Inc., now Ramp Corp. (RCO). Cymedix was a pioneer company in what was then known as i-health (Internet

healthcare) now the e-health industry. Mr. Berman's professional background provides the Company with business management experience and an in depth knowledge of our industry. Mr. Berman received a BA in 1975 and an MBA in 1977, from Indiana University.

Robert Jagunich has served as a Director of the Company since January of 2003. Mr. Jagunich has 29 years of experience in the medical systems and device industry. From August 1992 to present, he has held the position of President at New Abilities Systems, a privately held manufacturer of advanced electronic systems used in rehabilitation. He also provides consulting services to companies such as Johnson and Johnson and has served as a senior executive in such publicly held companies as Laserscope and Acuson. From April 1996 to December 1997 Mr. Jagunich acted as a director of Cymedix Corporation, the operating entity of Medix Resources, Inc., and later, Ramp Corp. (formerly AMEX:RCO). Mr. Jagunich's professional focus on medical devices as well as the professional relationships he has developed throughout his career provides the Company with opportunities to expand current markets and utilize additional product resources not previously available. He received his BS in 1969, and his MS and MBA in 1971, from the University of Michigan.

William Lyons has served as a Director of the company from January 2003 through October 2003 and most recently from January 2010 to the present time. Mr. Lyons is currently President and COO of Beacon Medical, Inc. a company specializing in the development, manufacturing, marketing and distribution of medical devices and instruments targeted primarily to the Plastic Surgery medical specialty. Prior to that, Mr. Lyons was co-founder, Executive Vice President and Director of BioElectronics Corporation. Mr. Lyons has successfully performed as President or Executive Vice President of several healthcare start-up communication technology and digital integration corporations. Mr. Lyons has also served in various executive positions for several fortune 500 companies such as American Sterilizer Company, Everest and Jennings and Allscrips. Mr. Lyon's professional experience with start-up companies in the medical technology industry as well as his knowledge in finance provide the Company with guidance in capital formation and sustainability. He holds an MBA in finance and a BA in Philosophy.

Mr. Berman, officer and director, works full-time for the company. Messrs. Jagunich and Lyons attend meetings of the board of directors when held and provides 20% and 25% respectively of their business time in professional capacities to the Company.

The following table sets forth information the remuneration of our Principal Executive officer for the three quarters ended 2016, and for the years ended December 31, 2015, 2014:

Summary Compensation Table

| Name and Principal Position | Year | Salary (\$) | Bonus (\$) | Stock Awards (\$) | Option Awards (\$) | Non-Equity Incentive Plan | Nonqualified Deferred Compensation | All Other Compensation | Total (\$) |
|-----------------------------|------|-------------|------------|-------------------|--------------------|---------------------------|------------------------------------|------------------------|------------|
| | | | | | | Compensation (\$) | Earnings (\$) | (\$) | |
| Keith Berman, CFO and PEO | 2014 | \$ -0- | -0- | \$ -0- | -0- | -0- | -0- | -0- | -0- |
| | 2015 | \$ -0- | -0- | \$ -0- | -0- | -0- | -0- | -0- | -0- |
| | 2016 | \$ -0- | -0- | \$ -0- | -0- | -0- | -0- | -0- | -0- |

Mr. Berman has served as Chief Financial Officer since January 2003 and as Principal Executive Officer since August 2006. During the fiscal years ended December 31, 2014 and 2015 and through September 30, 2016 Mr. Berman has received no cash compensation. Mr. Berman has not received any form of compensation as a result of our limited cash flow; Mr. Berman has agreed to accept stock awards as his compensation until such time the Company has the necessary resources available to provide a traditional compensation plan.

| Name of Beneficial Owner, Officer or Director | Number of Shares | Percent of Outstanding Shares of Common Stock ⁽¹⁾ |
|---|------------------|--|
|---|------------------|--|

| | | |
|---|------------------|--------------|
| Keith Berman, Chief Financial Officer and Director | 480,103 | <1.0% |
| Robert Jagunich, Director | 929,301 | 1.13% |
| William Lyons | - | - |
| Directors and Officers as a Group | <u>1,409,404</u> | <u>1.72%</u> |
| Barbara Asbell 7061 Los Coyotes Camarillo, CA 93012 | <u>1,162,590</u> | <u>1.42%</u> |
| Directors, Officers and Beneficial Owners as a Group | <u>2,571,994</u> | <u>3.14%</u> |

B. Legal/Disciplinary History. Please identify whether any of the foregoing persons have, in the last five years, been the subject of:

1. A conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding (excluding traffic violations and other minor offenses);

None

2. The entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, or banking activities;

None

3. A finding or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, or a state securities regulator of a violation of federal or state securities or commodities law, which finding or judgment has not been reversed, suspended, or vacated; or

None

4. The entry of an order by a self-regulatory organization that permanently or temporarily barred suspended or otherwise limited such person's involvement in any type of business or securities activities.

None

C. Beneficial Shareholders. Provide a list of the name, address and shareholdings or the percentage of shares owned by all persons beneficially owning more than ten percent (10%) of any class of the issuer's equity securities. If any of the beneficial shareholders are corporate shareholders, provide the name and address of the person(s) owning or controlling such corporate shareholders and the resident agents of the corporate shareholders.

None

9) Third Party Providers

Please provide the name, address, telephone number, and email address of each of the following outside providers that advise your company on matters relating to operations, business development and disclosure:

Legal Counsel

Name: Thomas C. Cook

Firm: Law Offices of Thomas C. Cook

OTC Markets Group Inc.

OTC Pink Basic Disclosure Guidelines (v1.1 April 25, 2013)

Address 1: 8250 W. Charleston Blvd. Ste. 120
Address 2: Las Vegas, NV 89117
Phone: (702) 242-0099
Email: tcesq@aol.com

10) Issuer Certification

The issuer shall include certifications by the chief executive officer and chief financial officer of the issuer (or any other persons with different titles, but having the same responsibilities).

CERTIFICATION

I, Keith Berman, certify that;

(1) I have reviewed this disclosure statement and Annual Reports for the periods ended September 30, 2016 and September 30, 2015.;

(2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

(3) Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

(4) The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) reevaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

(5) I have disclosed, based on our most recent evaluation of the internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions):

(a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: November 15, 2016

/s/Keith Berman

Keith Berman

Principal Executive Officer and a Director

(Principal Financial Officer)

**CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

The undersigned, Keith Berman, the Principal Executive Officer of Decision Diagnostics Corp., and Principal Financial Officer of Decision Diagnostics Corp., hereby certifies, that, to his knowledge, the Annual Report of Decision Diagnostics Corp. for the periods ended September 30, 2016, and September 30, 2015, fully complies with the requirements of this Disclosure Statement and of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and that the information contained in the Annual Report and this disclosure fairly presents in all material respects the financial condition and results of operations of Decision Diagnostics Corp. and its subsidiaries.

Date: November 15, 2016

/s/Keith Berman

Keith Berman

Principal Executive Officer and
Principal Financial Officer

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signatures that appear in typed form within the electronic version of this written statement required by Section 906, has been provided to Decision Diagnostics Corp. and will be retained by Decision Diagnostics Corp. and furnished to any regulatory body or OTC Markets, Inc. or their staff upon request.